Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 8/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 8/20 | 0.44 |
| ▸ | PRCP | P42785 | 6/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10201545 | 0.92 | CHEK2 (0.50) | HCRTR1HCRTR2CHEK2 | |
| SCHEMBL13125074 | 0.90 | UCHL1 (0.43) | HCRTR1HCRTR2PRCPCHEK2PTGES | |
| SCHEMBL13125056 | 0.90 | UCHL1 (0.43) | HCRTR1HCRTR2PRCPCHEK2PTGES | |
| SCHEMBL12509692 | 0.89 | HCRTR1 (0.46) | HCRTR1HCRTR2PRCPCHEK2PTGES | |
| SCHEMBL9605020 | 0.88 | PRCP (0.47) | HCRTR1HCRTR2PRCPCHEK2PTGES | |
| SCHEMBL13255599 | 0.88 | L3MBTL1 (0.50) | HCRTR1HCRTR2PTGES | |
| SCHEMBL9605028 | 0.88 | PRCP (0.47) | HCRTR1HCRTR2PRCPCHEK2PTGES | |
| SCHEMBL1982288 | 0.87 | HCRTR1 (0.49) | HCRTR1HCRTR2PRCPPTGES | |
| SCHEMBL1982286 | 0.87 | HCRTR1 (0.49) | HCRTR1HCRTR2PRCPPTGES | |
| SCHEMBL1043580 | 0.87 | PTGES (0.44) | HCRTR1HCRTR2PRCPPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| EP-2419404-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC (US) | 2015-11-04 | — | — | EP | disclosed |
| EP-2419404-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120935-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | WO | disclosed |
| US-20100267634-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267634-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | HCRTR1 4113/4885HCRTR2 4609/4885PRCP 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.